

REMARKS

Claims 1-23, 26, and 29-61 have been cancelled. As amended, the application contains Claim 24, 25, 27, and 28. No new claims have been added.

The claims have been rejected under 35 USC 102(b) in view of Biel, Elpern, Hermans et al., Ask et al., Burkholder et al., Taveras, and Tulshian et al. by the Examiner. Claims 6-9, 11-13, 15-17, 21, and 23-41 are rejected by the Examiner due to their dependency. However, the Examiner has strongly suggested that Applicants limit the claimed subject matter to the preferred embodiment of the invention as described in the specification at page 31, line 21 through page 32, line 17, which disclosure is also consistent with instant claim 22. The Examiner has also suggested that R¹, R², R³, X, and Y groups be limited to those of the preferred embodiment.


Applicants have amended Claim 24 such that it is now written in independent form and limited to those compounds in which Ring A is azabicyclo[3.2.1] octanyl (aka tropanyl) or piperidinyl and R¹, R², R³, X, and Y groups have been limited to those of the preferred embodiment.

In view of the cancellation and amendments to the claims it is respectfully submitted that the rejection under 35 USC 102 has been overcome. Therefore, is further requested that the Examiner review the remaining amended claims and allow the case.

It is respectfully submitted that the present application is now in condition for allowance.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


Bonnie Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 12 February 2009
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988